Treatment Methods for Early and Advanced Prostate Cancer
Management of biochemical recurrence following radiation therapy
Publication
, Chapter
Collins, TS; George, DJ
January 1, 2008
Introduction The introduction and use of the prostate-specific antigen (PSA) test has had a profound impact on the diagnosis and management of patients with prostate cancer. Prostate-specific antigen has gained wide acceptance as a screening tool for early detection of prostate cancer, yet it was originally developed as a tumor marker.1 As a tumor marker, PSA has demonstrated exceptional sensitivity and specificity for disease progression. One of the most important applications of PSA is its use in patients following definitive local therapy.
Duke Scholars
Publication Date
January 1, 2008
Start / End Page
213 / 219
Citation
APA
Chicago
ICMJE
MLA
NLM
Collins, T. S., & George, D. J. (2008). Management of biochemical recurrence following radiation therapy. In Treatment Methods for Early and Advanced Prostate Cancer (pp. 213–219).
Collins, T. S., and D. J. George. “Management of biochemical recurrence following radiation therapy.” In Treatment Methods for Early and Advanced Prostate Cancer, 213–19, 2008.
Collins TS, George DJ. Management of biochemical recurrence following radiation therapy. In: Treatment Methods for Early and Advanced Prostate Cancer. 2008. p. 213–9.
Collins, T. S., and D. J. George. “Management of biochemical recurrence following radiation therapy.” Treatment Methods for Early and Advanced Prostate Cancer, 2008, pp. 213–19.
Collins TS, George DJ. Management of biochemical recurrence following radiation therapy. Treatment Methods for Early and Advanced Prostate Cancer. 2008. p. 213–219.
Publication Date
January 1, 2008
Start / End Page
213 / 219